Table 3 Univariate effect of the non-weighted average CsA level between day 0 and day +14 post transplantation

From: Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival

Outcomes N Day 100 incidence (95% CI), % P-test for trend
Grade II–IV acute GVHD
 Average CsA level in ng/mL
<200 26 51 (40–62) 0.04
200–249 62 47 (34–60)  
250–299 93 47 (36–58)  
300–349 91 47 (36–58)  
350+ 65 35 (25–45)  
Non-relapse mortality
 Average CsA level in ng/mL
<200 26 40 (20–60) 0.02
200–249 62 36 (23–49)  
250–299 93 25 (15–35)  
300–349 91 25 (15–35)  
350+ 65 22 (13–31)  
OS
 Average CsA level in ng/mL
<200 26 38 (19–57) 0.07
200–249 62 37 (24–51)  
250–299 93 46 (33–59)  
300–349 91 35 (23–47)  
350+ 65 46 (31–61)  
  1. Statistically significant P values are in bold.